Mode
Text Size
Log in / Sign up
N/A N=480 Randomized Single-blind Prevention

Maternal Lifestyle and Neonatal Hypoglycemia

Hyperinsulinemia · Miscarriages · Pregnancy · Sedentary Lifestyle · Hypoglycemia

Enrolled (actual)
480
Serious AEs
23.8%
Results posted
Jan 2016
Primary outcome: Primary: Neonatal Hypoglycemia — 3; 15 neonates

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Daily brisk walking plus a carbohydrate-restricted diet (Behavioral)
Age
Pediatric, Adult
Sex
All
Sponsor
Hospital dos Servidores do Estado do Rio de Janeiro
Primary completion
Apr 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Neonatal Hypoglycemia
3; 15
SECONDARY
Refractory Hypoglycemia
0; 3

Summary

tPA has a pivotal role in placentation, mediationg activation of growth factors, such as vascular endothelial growth factor and brain-derived neurotrophic factor, degradation of extracellular matrix and basement membrane (directly or through activation of matrix metalloproteinases) and formation of hemidesmosomes. A high-carbohydrate intake combined with lack of physical activity provides a strong stimulus for maternal insulin production. In this scenario, either β-cells are dysfunctional and diabetes supervenes, or excessive amounts of insulin are produced, providing pathological stimulation of PAI-1 synthesis. Given that PAI-1 is a major tPA inhibitor, PAI-1 excess may affect placentation, increasing the risk of first trimester losses, preterm deliveries and intrauterine growth restriction. Our hypothesis was that prematurity was not the cause of neonatal hypoglycemia, but a parallel occurrence of a strong stimulus for maternal, fetal and neonatal production of insulin.

Eligibility Criteria

Inclusion criteria: recurrent early unexplained miscarriages Exclusion criteria: (i) antiphospholipid antibodies, (ii) second- or third-trimester losses, (iii) multiple pregnancy, (iv) anatomical abnormalities that could increase the risk of early miscarriages, (iv) any condition requiring a priori anticoagulation, (v) protocol violation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01409382). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search